drugset / Trial / NCT02861690
Liposomal Paclitaxel Combined Nedaplatin in Treatment of Advanced or Recurrent Esophageal Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, tolerance and efficacy of Liposomal Paclitaxel With Nedaplatin as First-line in patients with Advanced or Recurrent Esophageal Carcinoma
Timeline
- Start
- 2010-01
- Primary completion
- 2015-09
- Completion
- 2016-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nedaplatin | Small molecule | 80 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 175 mg/m2 | — |